                               SEQUENCE LISTING

<110> ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF 
      ARIZONA, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY
 
<120> METHODS FOR DISCOVERING THERAPEUTIC TARGETS

<130> 43638-708.601

<140> PCT/US2013/058325
<141> 2013-09-05

<150> 14/014,168
<151> 2013-08-29

<150> 61/696,873
<151> 2012-09-05

<160> 17    

<170> PatentIn version 3.5

<210> 1
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 1
Lys Ser Phe His Gly Arg Val Ile Gln Asp Val Val Gly Glu Pro Tyr 
1               5                   10                  15      


Gly Gly Ser Cys 
            20  


<210> 2
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 2
Pro Ala Met Lys His Arg Glu Pro His Trp Val Ile Pro Gly Ile Ile 
1               5                   10                  15      


Trp Gly Ser Cys 
            20  


<210> 3
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 3
Glu Pro Met Glu Met His Asp Asp Arg Thr Met Arg Pro Asn Gly Ala 
1               5                   10                  15      


Phe Gly Ser Cys 
            20  


<210> 4
<211> 12
<212> PRT
<213> Influenza A virus

<400> 4
Ser Trp Arg Lys Lys Ile Leu Arg Thr Gln Glu Ser 
1               5                   10          


<210> 5
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 5
Val Ile Gln Asp Val Val Gly Glu 
1               5               


<210> 6
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MOD_RES
<222> (6)..(6)
<223> Val or Leu

<400> 6
Val Ile Gln Asp Val Xaa Gly Glu 
1               5               


<210> 7
<211> 8
<212> PRT
<213> Mus sp.

<400> 7
Val Ile Asp Gln Val Leu Gly Glu 
1               5               


<210> 8
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 8
Phe His Gly Arg Val Ile Gln 
1               5           


<210> 9
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MOD_RES
<222> (6)..(6)
<223> Ile or Thr

<400> 9
Phe His Gly Arg Val Xaa Gln 
1               5           


<210> 10
<211> 7
<212> PRT
<213> Mus sp.

<400> 10
Phe His Gly Arg Val Thr Gln 
1               5           


<210> 11
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 11
Glu Pro Met Glu Met His Asp Asp Arg Thr Met Arg Pro Asn Gly Ala 
1               5                   10                  15      


Phe 
    


<210> 12
<211> 57
<212> PRT
<213> Influenza A virus

<400> 12
Glu Glu Lys Arg Gln Leu Lys Lys Gly Leu Lys Ser Gln Glu Gln Cys 
1               5                   10                  15      


Ala Ser Leu Pro Thr Lys Val Ser Arg Arg Thr Ser Pro Ala Leu Lys 
            20                  25                  30          


Ile Leu Glu Pro Met Trp Met Asp Ser Asn Arg Thr Ala Thr Leu Arg 
        35                  40                  45              


Ala Ser Cys Leu Lys Cys Pro Lys Lys 
    50                  55          


<210> 13
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 13
Pro Ala Met Lys His Arg Glu Pro His Trp Val Ile Pro Gly Ile Ile 
1               5                   10                  15      


Trp 
    


<210> 14
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 14
Glu Glu Lys Arg Gln Leu Lys Lys Gly Leu Lys Ser Gln Glu Gln Cys 
1               5                   10                  15      


Ala Gly Ser Cys 
            20  


<210> 15
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 15
Gln Cys Ala Ser Leu Pro Thr Lys Val Ser Arg Arg Thr Ser Pro Ala 
1               5                   10                  15      


Leu Gly Ser Cys 
            20  


<210> 16
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 16
Pro Ala Leu Lys Ile Leu Glu Pro Met Trp Met Asp Ser Asn Arg Thr 
1               5                   10                  15      


Ala Gly Ser Cys 
            20  


<210> 17
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 17
Ser Asn Arg Thr Ala Thr Leu Arg Ala Ser Cys Leu Lys Cys Pro Lys 
1               5                   10                  15      


Lys Gly Ser Cys 
            20  


